GILD vs VRTX vs INSM Stock Comparison

Gilead Sciences, Vertex Pharmaceuticals and Insmed Prices as of Nov 13, 2026 Peers: Industry group
GILD Gilead Sciences, Inc.
$168.08 +9.5% 1M +34.2% 1Y
Market cap
$208.49B
P/E
–
Revenue (TTM)
$30.99B
Div. yield
–
Biotechnology Healthcare
4 wins
INSM INSMED Inc
$121.16 +23.9% 1M -36.6% 1Y
Market cap
$26.96B
P/E
–
Revenue (TTM)
$1.52B
Div. yield
–
Biotechnology Healthcare
2 wins

Head to Head

9 decided of 12

Gilead Sciences leads on 4 of the 12 questions below (Gilead Sciences 4, Vertex Pharmaceuticals 3, Insmed 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionGILDVRTXINSMLeader
Larger companyMarket capitalisation $208.49B $135.89B $26.96B GILD
Cheaper on earningsLower P/E, profitable companies only -54.0x 34.2x -44.5x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS — 30.4x — –
Faster revenue growthRevenue growth, trailing twelve months +6.5% +10.5% +240.0% INSM
More profitableNet margin, trailing twelve months -12.5% 30.7% -39.9% VRTX
Better return on capitalReturn on invested capital -6.1% — -41.1% GILD
Less leveragedLower net debt / EBITDA 43.8x -0.4x 1.1x VRTX
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +34.2% +24.0% -36.6% GILD
Better 5-year returnAnnualised price return, 5 years +20.0%/yr +23.5%/yr +30.6%/yr INSM
Less volatileAnnualised volatility, 1 year 27.5% 29.5% 62.2% GILD
Higher overall scoreMean of the five percentile scores vs peers 61/100 73/100 66/100 VRTX

Percentile Scorecard

GILDVRTXINSM

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisGILDVRTXINSM
Valuation 89 #71 of 660 77 #152 of 660 70 #201 of 660
Growth 34 #408 of 619 46 #333 of 619 85 #91 of 619
Profitability 85 #91 of 595 93 #40 of 595 69 #186 of 595
Financial Health 22 #530 of 683 55 #311 of 683 37 #428 of 683
Shareholder Returns 75 #116 of 459 92 #37 of 459 67 #153 of 459
Overall 61 73 66
  • GILD ranked among 695 companies in Pharmaceuticals and Biotechnology
  • VRTX ranked among 695 companies in Pharmaceuticals and Biotechnology
  • INSM ranked among 695 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodGILDVRTXINSMSPY
1 month +9.5%+8.0%+23.9% -2.0%
3 months +21.5%+6.5%-2.1% -2.8%
6 months +29.7%+23.3%+11.0% +2.0%
Year to date +36.9%+18.8%-30.4% +10.6%
1 year +34.2%+24.0%-36.6% +12.2%
3 years +124.9%+45.6%+393.7% +68.1%
3 years, per year +31.1%+13.3%+70.3% +18.9%
5 years +149.1%+187.6%+280.3% +61.4%
5 years, per year +20.0%+23.5%+30.6% +10.1%
10 years +119.9%+485.4%+738.5% +248.5%
10 years, per year +8.2%+19.3%+23.7% +13.3%

Risk

MeasureGILDVRTXINSMSPY
Volatility, 1Y 27.5%29.5%62.2% 13.6%
Downside volatility, 1Y 24.0%26.1%61.0% 13.9%
Beta vs S&P 500, 1Y 0.390.430.55 1.00
Return / volatility, 1Y 1.250.81-0.59 0.90
Max drawdown, 5Y -29.4%-29.1%-56.5% -25.4%
From 52-week high -3.7%-3.6%-42.7% -3.2%
52-week high $174.48$558.71$211.41 $779.14
52-week low $118.30$421.03$91.88 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleGILDVRTXINSM
P/E now vs peer median -54.0xmedian 17.0x 34.3xmedian 17.0x -43.8xmedian 17.0x
P/S now vs peer median 6.7xmedian 8.4x 10.5xmedian 8.4x 17.5xmedian 8.4x
EV/EBITDA now vs peer median 505.3xmedian 14.6x 29.7xmedian 14.6x -48.6xmedian 14.6x
P/FCF now vs peer median 15.1xmedian 19.0x 42.6xmedian 19.0x -42.3xmedian 19.0x
P/B now vs peer median 16.0xmedian 2.0x 6.5xmedian 2.0x 36.6xmedian 2.0x
PEG now vs peer median 1.40median 0.43 6.39median 0.43 -2.40median 0.43

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsGILDVRTXINSM
Revenue $30.99B $12.95B $1.52B
Gross profit $24.77B $11.08B $1.28B
Operating income -$2.36B $4.30B -$563.99M
Net income -$3.86B $3.98B -$605.67M
Free cash flow $13.78B $3.20B -$627.58M
R&D $6.33B $4.25B $944.39M
EPS (diluted) $-3.09 $15.58 $-2.77
Cash & equivalents $6.44B $4.98B $396.60M
Total debt $26.23B $4.50B $555.09M
Shares (diluted) 1.25B 255.20M 218.79M
Enterprise value $183.60B $103.63B $22.00B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricGILDVRTXINSM
P/E -54.0x 34.3x -43.8x
P/FCF 15.1x 42.6x -42.3x
P/Operating cash flow 14.4x 37.0x -44.6x
P/S 6.7x 10.5x 17.5x
P/B 16.0x 6.5x 36.6x
P/Tangible book -543.2x 11.0x 45.2x
EV/EBITDA 505.3x 29.7x -48.6x
EV/EBIT -96.7x 31.3x -46.1x
EV/Revenue 7.4x 10.4x 17.1x
EV/FCF 16.6x 42.1x -41.4x
EV/Operating cash flow 15.8x 36.5x -43.6x
PEG (3Y EPS CAGR) 1.40 6.39 -2.40

Growth

14 metrics
MetricGILDVRTXINSM
Revenue growth (1Y) 6.5% 10.5% 240.0%
Revenue CAGR (3Y) 4.2% 10.3% 75.6%
Gross profit growth (1Y) 8.2% 9.5% 274.9%
Gross profit CAGR (3Y) 4.7% 9.3% 79.8%
Operating income growth (1Y) -122.5% 7.8% 51.3%
Operating income CAGR (3Y) -31.7% 3.5% 6.2%
Net income growth (1Y) -147.6% 8.2% 48.8%
Net income CAGR (3Y) -38.5% 4.6% 5.8%
EPS growth (1Y) -147.7% 9.2% 50.5%
EPS CAGR (3Y) -38.6% 5.4% 18.2%
Operating cash flow growth (1Y) 49.8% -0.6% 32.6%
Operating cash flow CAGR (3Y) 19.9% -5.5% -5.4%
Free cash flow growth (1Y) 50.4% -4.0% 30.7%
Free cash flow CAGR (3Y) 20.6% -8.7% -6.2%

Profitability

14 metrics
MetricGILDVRTXINSM
Gross margin 79.9% 85.5% 84.4%
EBITDA margin 1.5% 35.1% -35.1%
Operating margin -7.6% 33.2% -37.1%
Pretax margin -8.2% 36.7% -39.4%
Net margin -12.5% 30.7% -39.9%
FCF margin 44.5% 24.7% -41.3%
Operating cash flow margin 46.7% 28.5% -39.2%
Return on equity -31.2% 19.3% -81.9%
Return on assets -7.7% 13.2% -28.1%
Return on invested capital -6.1% – -41.1%
Return on capital employed -6.2% 17.2% -36.0%
Asset turnover 0.6x 0.4x 0.7x
Cash conversion (OCF / net income) -3.7x 0.9x 1.0x
Stock comp / revenue 2.9% 5.2% 11.0%

Financial Health

11 metrics
MetricGILDVRTXINSM
Debt / assets 51.0% 13.7% 24.9%
Debt / equity 2.0x 0.2x 0.8x
Net debt / EBITDA 43.8x -0.4x 1.1x
Debt / FCF 1.9x 1.4x -0.9x
Liabilities / assets 74.6% 36.1% 67.4%
Equity / assets 25.4% 63.9% 32.6%
Interest coverage -2.3x 93.0x -5.5x
Current ratio 1.4x 2.3x 2.9x
Quick ratio 1.0x 1.7x 2.4x
Cash ratio 0.5x 1.3x 1.9x
Altman Z-score 3.90 8.70 7.36

Shareholder Returns

7 metrics
MetricGILDVRTXINSM
Dividend yield 1.9% – –
Net buyback yield 0.5% 0.7% -0.4%
Shareholder yield 2.5% 0.7% -0.4%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusGILDVRTXINSM
Forward P/E – 30.4xFY2026 –
EPS, next fiscal year $-0.84FY2026 $17.71FY2026 $-1.68FY2026
EPS growth, next FY -110.3%FY2026 -3.7%FY2026 –
EPS growth, the year after – +20.2% –
Revenue, next fiscal year $29.15BFY2026 $12.68BFY2026 $1.99BFY2026
Revenue growth, next FY -1.0%FY2026 +5.9%FY2026 +227.7%FY2026
Revenue growth, the year after +18.3% +19.2% +59.5%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersGILDVRTXINSM
Held by institutions 89.6% 95.1% 100.0%
Institutions holding 2,293 1,747 671
Change in shares held, QoQ +5.1% +3.9% +3.4%
Institutions buying 1,113 904 369
Institutions selling 853 605 230
Buyers to sellers 1.30 1.49 1.60

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

GILDVRTXINSM
GILD 1.00 0.51 0.19
VRTX 0.51 1.00 0.25
INSM 0.19 0.25 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, GILD, VRTX and INSM?

Gilead Sciences (GILD) is the largest by market capitalisation: Gilead Sciences (GILD) $208.49B, Vertex Pharmaceuticals (VRTX) $135.89B, Insmed (INSM) $26.96B.

Which company is growing faster?

Insmed (INSM) grew revenue fastest over the trailing twelve months: Gilead Sciences (GILD) +6.5%, Vertex Pharmaceuticals (VRTX) +10.5%, Insmed (INSM) +240.0%.

Which company is more profitable?

Vertex Pharmaceuticals (VRTX) has the highest net margin (Gilead Sciences (GILD) -12.5%, Vertex Pharmaceuticals (VRTX) 30.7%, Insmed (INSM) -39.9%). On return on invested capital, Gilead Sciences (GILD) leads (Gilead Sciences (GILD) -6.1%, Insmed (INSM) -41.1%).

Which stock has performed better?

Over the past year Gilead Sciences (GILD) returned the most: Gilead Sciences (GILD) +34.2%, Vertex Pharmaceuticals (VRTX) +24.0%, Insmed (INSM) -36.6%. Over five years, Insmed (INSM) compounded fastest (Gilead Sciences (GILD) +20.0%/yr, Vertex Pharmaceuticals (VRTX) +23.5%/yr, Insmed (INSM) +30.6%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Gilead Sciences (GILD) has been the steadiest (Gilead Sciences (GILD) 27.5%, Vertex Pharmaceuticals (VRTX) 29.5%, Insmed (INSM) 62.2%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, GILD, VRTX and INSM?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Gilead Sciences (GILD) leads on 4. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.